- Auteur(s) : Laetitia Coutte, Chantal Dreyer, Marie-Paule Sablin, Sandrine Faivre, Éric Raymond
, Hôpital Beaujon, service interhospitalier de cancérologie, 100, boulevard du Général-Leclerc, 92118 Clichy Cedex, France
- Mots-clés : PI3K-AKT, mTOR, everolimus, renal cancer
- Page(s) : 173-80
- DOI : 10.1684/bdc.2011.1384
- Année de parution : 2012
PI3K/AKT/mTOR pathway is an intracellular signalling pathway composed of different kinases. Many protein mutations are described in that pathway, and are responsible of dysregulation of cell growth, proliferation, survival and angiogenesis. Rapamycin is an antibiotic inhibiting mTOR. Different analogs of rapamycin are developped or being developped in antitumoral therapy, in which temsirolimus, everolimus and deforolimus, demonstrated antitumoral activity in renal cancer and mantle cell lymphoma, and many clinical trials are in progress in other tumors. In the future, predictive factors of response need to be identified; patient selection and associations with chemotherapy or with other targeted therapies should be explored.